To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have DLBCL that has returned despite prior chemotherapy and contains a mutated form of the CD79 gene.
- At least 2 weeks must have passed since completion of prior chemotherapy (4 weeks since receipt of biologic drugs, such as antibodies) and entry into the study.
- This study is open to patients age 18 and older.
For more information and to inquire about eligibility for this study, please contact Dr. John Gerecitano at 212-639-3748.